An analysis by the staff of the Food and Drug Administration appeared to dim the prospects that Genentech's drug Avastin would win approval as a treatment for breast cancer. The drug did not help women with breast cancer live meaningfully longer, the agency staff said, and it caused significant side effects.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment